Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 1/2019

01-01-2019 | Original Article

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy

Authors: Seiichi Kato, Makoto Kawase, Daiki Kato, Takashi Ishida, Masahiro Uno, Yoshinori Fujimoto, Takako Masue, Naruyasu Masue, Takashi Deguchi

Published in: Journal of Bone and Mineral Metabolism | Issue 1/2019

Login to get access

Abstract

The aim of this study was to conduct a cross-sectional survey of investigations related to the bone mineral density (BMD) of both non-metastatic prostate cancer (NMPC) patients who have not yet received androgen deprivation therapy (ADT) and patients receiving prolonged ADT in Japan. Japanese male patients with NMPC who received continuous ADT or who were planning to receive ADT were enrolled in this study. Lumbar spine and femoral neck BMD was measured using dual-energy X-ray absorptiometry (DEXA). To assess patient characteristics, we searched medical records and questionnaires to determine whether they had any factors that could possibly affect BMD. A total of 230 patients with a mean age of 76.6 ± 6.4 years were evaluated. Of these, 151 (65.7%) were receiving ADT, and 79 (34.4%) had not yet received ADT. The mean duration of ADT was 37.4 ± 30.7 months. DEXA showed that as the duration of ADT increased, lumbar spine and femoral neck BMD decreased gradually (p = 0.0005 and p = 0.0014, respectively). Stepwise regression analyses revealed that the duration of ADT was a significant variable of both lumbar spine and femoral neck BMD. Moreover, as the duration of ADT increased, the prevalence of osteoporosis increased statistically (p = 0.0002). This study showed that ADT negatively affected lumbar spine and femoral neck BMD. It also showed a progressive increase in the prevalence of osteoporosis in Japanese NMPC patients with ADT.
Literature
1.
go back to reference Cancer Registration Committee of the Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61CrossRef Cancer Registration Committee of the Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61CrossRef
2.
go back to reference Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504CrossRefPubMed Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504CrossRefPubMed
3.
go back to reference Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of multicenter phase 3 clinical study. J Urol 179:152–155CrossRefPubMed Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of multicenter phase 3 clinical study. J Urol 179:152–155CrossRefPubMed
4.
go back to reference Gilbert SM, McKiernan JM (2005) Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 15:23–27CrossRefPubMed Gilbert SM, McKiernan JM (2005) Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 15:23–27CrossRefPubMed
5.
go back to reference Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417CrossRefPubMed Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417CrossRefPubMed
6.
go back to reference ShahinianVB Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164CrossRef ShahinianVB Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164CrossRef
7.
go back to reference Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL (2005) Gonadotropin-releasing hormone agonisits and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897–7903CrossRefPubMed Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL (2005) Gonadotropin-releasing hormone agonisits and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897–7903CrossRefPubMed
8.
go back to reference Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007CrossRefPubMed Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007CrossRefPubMed
9.
go back to reference Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at primary health-care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases, University of Sheffield, UK Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at primary health-care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases, University of Sheffield, UK
10.
go back to reference Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2005) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679–1683CrossRef Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2005) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679–1683CrossRef
11.
go back to reference Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104:800–805CrossRefPubMed Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104:800–805CrossRefPubMed
12.
go back to reference Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR (2011) Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol 186:482–486CrossRefPubMedPubMedCentral Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR (2011) Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol 186:482–486CrossRefPubMedPubMedCentral
13.
go back to reference Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL (2011) Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom 14:348–353CrossRefPubMedPubMedCentral Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL (2011) Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom 14:348–353CrossRefPubMedPubMedCentral
14.
go back to reference Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T (2010) Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75:1131–1137CrossRefPubMed Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T (2010) Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75:1131–1137CrossRefPubMed
15.
go back to reference Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K (2000) Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449–452CrossRefPubMed Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K (2000) Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449–452CrossRefPubMed
16.
go back to reference Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H (2004) Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64:128–131CrossRefPubMed Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H (2004) Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64:128–131CrossRefPubMed
17.
go back to reference Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma. Cancer 115:3468–3474CrossRefPubMed Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma. Cancer 115:3468–3474CrossRefPubMed
18.
go back to reference Israeli RS, Ryan CW, Jung L (2008) Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179:414–423CrossRefPubMed Israeli RS, Ryan CW, Jung L (2008) Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179:414–423CrossRefPubMed
20.
go back to reference Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, Mcclung M, Hosking D, Yates AJ, Christiansen C (1999) Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622–1627CrossRefPubMed Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, Mcclung M, Hosking D, Yates AJ, Christiansen C (1999) Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622–1627CrossRefPubMed
21.
go back to reference Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70:122–126CrossRefPubMed Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT (2007) Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70:122–126CrossRefPubMed
22.
go back to reference Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes−a meta-analysis. Osteoporos Int 18:427–444CrossRefPubMed Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes−a meta-analysis. Osteoporos Int 18:427–444CrossRefPubMed
23.
go back to reference Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED (2017) Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int 119:239–244CrossRefPubMed Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED (2017) Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int 119:239–244CrossRefPubMed
24.
go back to reference Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS (2001) Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91:2238–2245CrossRefPubMed Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS (2001) Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91:2238–2245CrossRefPubMed
Metadata
Title
Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy
Authors
Seiichi Kato
Makoto Kawase
Daiki Kato
Takashi Ishida
Masahiro Uno
Yoshinori Fujimoto
Takako Masue
Naruyasu Masue
Takashi Deguchi
Publication date
01-01-2019
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 1/2019
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-017-0897-5

Other articles of this Issue 1/2019

Journal of Bone and Mineral Metabolism 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine